Six-Weekly Low-Dose Nivolumab Combined with Oral Triple Metronomic Chemotherapy for Advanced Cancers of the Head and Neck: An Open-Label, Prospective, Single-Institution Experience from Eastern India

Head and neck cancer is a formidable disease that strikes the tissues lining the mouth, throat, and voice box. In many parts of the world, particularly in developing nations, it remains a leading cause of cancer death, often driven by habits like chewing tobacco. When this cancer returns after treatment or spreads to other parts of the body, the outlook becomes grim. For decades, the standard approach involved powerful chemotherapy drugs, but these often came with severe side effects and offered only limited time gains. Recently, a new class of medicine called immunotherapy has changed the landscape. These drugs do not poison the cancer directly; instead, they remove the invisible shields that cancer cells use to hide from the body's own immune system, allowing the immune cells to recognize and attack the tumor. While this approach has shown great promise, the cost of these treatments is so high that the vast majority of patients in countries like India cannot afford them, leaving a desperate gap between what is medically possible and what is financially accessible.

Researchers at a hospital in Bhubaneswar, India, set out to bridge this gap by testing a modified version of this life-saving treatment. They focused on a specific immunotherapy drug called nivolumab, which is typically given in large doses every few weeks. The team wondered if a much smaller dose, given less frequently, could still work effectively when combined with a simple, low-cost cocktail of three oral drugs taken daily. This oral combination, known as triple metronomic chemotherapy, consists of methotrexate, erlotinib, and celecoxib. The idea was to create a regimen that was gentle enough to be affordable for everyday people but potent enough to fight the disease. They enrolled sixty-five adults with advanced head and neck cancer who had no other treatment options. Every patient received the daily oral drugs, and in addition, they were given a single, low dose of the immunotherapy injection once every six weeks. This schedule was designed to keep patients out of the hospital as much as possible, reducing the burden of travel and time away from their families.

The results of this trial offered a hopeful signal for patients with limited resources. Over the course of the study, the treatment proved to be effective. More than half of the patients saw their tumors shrink significantly or disappear entirely within six months. The time patients lived without their disease getting worse averaged eight months, and the total time they survived after starting the treatment averaged nearly twelve months. These numbers are comparable to the results seen with much more expensive, standard-dose immunotherapy regimens used elsewhere. The researchers also found that the treatment was safe. While almost every patient experienced some side effect, such as fatigue or a dry mouth, the severe reactions were rare. Only a small fraction of patients experienced serious complications like severe mouth sores or low blood counts, and no one died as a direct result of the treatment itself. Interestingly, the data showed that men in the study tended to live longer than women, though the reasons for this difference were not explained by the study.

Perhaps the most significant finding was that the treatment worked just as well regardless of whether the patients had previously been treated with platinum-based chemotherapy. This means the approach is versatile, offering a viable path for patients who have already tried and failed other standard treatments. The study suggests that by lowering the dose of the expensive antibody and spacing it out to once every six weeks, doctors can achieve similar survival benefits while drastically cutting the cost and the number of hospital visits required. For a population where the standard high-dose treatment is financially out of reach for nearly everyone, this modified schedule represents a practical and accessible alternative. It demonstrates that effective cancer care does not always require the most expensive tools, but rather a careful balance of biology, timing, and affordability. The researchers conclude that this approach could become a new standard of care for patients in similar economic settings, offering a realistic chance at extended life without the crushing financial burden that currently blocks access to modern medicine.